Host: Matt Birnholz, MD

Guest: Alain Mita, MD, MSc

Each year more people die of lung cancer than of colon, breast, and prostate cancers combined. Non-small cell lung cancer, which accounts for 85% of lung cancer cases, has been the key target of several clinical trials evaluating new immune-modifying agents. Dr. Alan Mita, Associate Professor of Medicine and Co-Director of Experimental Therapeutics at the Samuel Oschin Comprehensive Cancer Institute of Cedar Sinai Medical Center in Los Angeles joins host, Dr. Matt Birnholz, to discuss one such drug therapy entering this immune oncology space and ways for oncologists treating patients with non-small cell lung cancer to get involved in this drug’s global phase 3 trial directly. To inquire about participating in the trial please contact BeyondSpring Pharmaceuticals at [email protected].